Skip to main content

8 Result(s)

within Editta Baldini Remove this filter

and

  1. Article

    Open Access

    Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study

    Cytidine deaminase (CDA) plays a crucial role in the degradation of gemcitabine. In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and efficacy ...

    Carmelo Tibaldi, Andrea Camerini, Marcello Tiseo… in British Journal of Cancer (2018)

    Download PDF (433 KB) View Article

  2. Article

    Open Access

    EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

    We aimed at investigating the outcomes of female patients with stage IIIB-IV adenocarcinoma of the lung according to EGFR and K-Ras mutational status.

    Virginia Rotella, Lorenzo Fornaro… in Journal of Experimental & Clinical Cancer … (2014)

    Download PDF (458 KB) View Article

  3. Article

    Open Access

    Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study

    The prognosis of pT1a-pT1b breast cancer (BC) used to be considered very good, with a 10-y RFS of 90%. However, some retrospective studies reported a 10-y RFS of 81%–86% and suggested benefit from adjuvant sys...

    Stefania Gori, Matteo Clavarezza, Salvatore Siena, Jennifer Foglietta… in BMC Cancer (2012)

    Download PDF (318 KB) View Article

  4. No Access

    Article

    Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

    Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin...

    Dino Amadori, Rosella Silvestrini, Mario De Lena… in Breast Cancer Research and Treatment (2011)

  5. No Access

    Article

    Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)

    Abstract

    Editta Baldini, Andrea Ardizzoni, Tiziana Prochilo… in Cancer Chemotherapy and Pharmacology (2002)

  6. No Access

    Article

    Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

    Purpose. To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as induction before h...

    Pier Franco Conte, Alessandra Gennari, Sara Donati… in Breast Cancer Research and Treatment (2001)

  7. No Access

    Article

    Epirubicin/vinorelbine as first line therapy in metastatic breast cancer

    This study was aimed at investigating the toxicity and activity of the combination epirubicin and vinorelbine in chemotherapy-naive patients with metastatic breast cancer. Fifty-one patients with measurable or...

    Editta Baldini, Carmelo Tibaldi, Franco Chiavacci… in Breast Cancer Research and Treatment (1998)

  8. No Access

    Article

    Intraperitoneal infusion of interleukin-2 in patients with malignant ascites: Phenotypic and functional effects on tumor-associated lymphocytes

    The aim of the present study was to evaluate the effects of intraperitoneal interleukin-2 (IL-2) infusion on tumor-associated lymphocytes (TAL) and peripheral blood lymphocytes (PBL) in patients with malignant...

    Giovanni Melioli, Editta Baldini, Andrea De Maria… in Ricerca in clinica e in laboratorio (1988)